Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J8OC
|
|||
| Former ID |
DPR000104
|
|||
| Drug Name |
Scriptaid
|
|||
| Synonyms |
CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Preclinical | [1], [2] | |
| Company |
Alexis Biochemicals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H18N2O4
|
|||
| Canonical SMILES |
C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO
|
|||
| InChI |
1S/C18H18N2O4/c21-15(19-24)10-2-1-3-11-20-17(22)13-8-4-6-12-7-5-9-14(16(12)13)18(20)23/h4-9,24H,1-3,10-11H2,(H,19,21)
|
|||
| InChIKey |
JTDYUFSDZATMKU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 287383-59-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3306176, 3927063, 4514382, 8153184, 11133360, 12015626, 12159065, 14924112, 26759501, 29215541, 29224244, 52444651, 53800539, 57322641, 85736422, 85787123, 87218816, 87226486, 87929802, 92098539, 99375469, 103100129, 103311545, 104308508, 104815810, 117597804, 118293820, 123107793, 125333833, 131332432, 134339544, 134964532, 135698094, 140402267, 143417840, 144020551, 144183025, 160830070, 162023417, 162248317, 163081722, 163394399, 163620928, 163686249, 163687353, 164193984, 164764973, 165247634, 165348198, 172107269
|
|||
| ChEBI ID |
CHEBI:92401
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7505). | |||
| REF 2 | Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. | |||
| REF 3 | Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. | |||
| REF 4 | Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.